Arrowhead Pharmaceuticals, Inc. (ARWR) News

Arrowhead Pharmaceuticals, Inc. (ARWR)

Today's Latest Price: $33.31 USD

1.07 (3.32%)

Updated Jun 1 6:55pm

Add ARWR to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

Filter ARWR News Items

ARWR News Results

Event/TimeSymbolCompanyNews DetailStartEndChangePOWR Rating
Loading, please wait...

Latest ARWR News From Around the Web

Below are the latest news stories about Arrowhead Pharmaceuticals Inc that investors may wish to consider to help them evaluate ARWR as an investment opportunity.

Arrowhead Pharmaceuticals to Participate in Upcoming June 2020 Conferences

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals will present at Jefferies and Goldman Sachs healthcare conferences in June 2020

Business Wire | May 28, 2020

Is Arrowhead Pharmaceuticals a Buy?

The development-stage genetic medicine company is eager to convert its intriguing potential into tangible progress.

Yahoo | May 24, 2020

Arrowhead Pharmaceuticals Is Likely to See a Trading Range Market Ahead

I would look for further sideways trading on ARWR….ARWR

The Street RealMoney | May 22, 2020

Will Arrowhead Pharmaceuticals Be a Biotech Winner?

A leading company in the field of gene silencing is on track to develop several breakthrough therapies.

Yahoo | May 19, 2020

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Investors in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) had a good week, as its shares rose 4.9% to close at...

Yahoo | May 10, 2020

Edited Transcript of ARWR earnings conference call or presentation 7-May-20 8:30pm GMT

Q2 2020 Arrowhead Pharmaceuticals Inc Earnings Call

Yahoo | May 9, 2020

Arrowhead Pharmaceuticals, Inc (ARWR) Q2 2020 Earnings Call Transcript

Thank you for joining us today to discuss Arrowhead's results for its fiscal second quarter ended March 31, 2020. With us today from management are President and CEO, Dr. Christopher Anzalone, who will provide an overview of the quarter; Dr. Javier San Martin, Chief Medical Officer who will discuss our clinical programs; Dr. Curt Bradshaw, our Chief Scientific Officer who will discuss our discovery, platform development and manufacturing efforts; and Ken Myszkowski, our Chief Financial Officer, who will give a review of the financials.

Yahoo | May 9, 2020

Arrowhead Pharmaceuticals, Inc (ARWR) Q2 2020 Earnings Call Transcript | The Motley Fool

ARWR earnings call for the period ending March 31, 2020.

The Motley Fool | May 8, 2020

Arrowhead Pharmaceuticals Reports Fiscal 2020 Second Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals reports fiscal Q2 2020 earnings

Business Wire | May 7, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming May 2020 Conferences

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead will present at upcoming May 2020 investor conferences

Business Wire | May 1, 2020

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6758 seconds.